Ask AI

Search

Updates

Loading...

Table of contents

Acne vulgaris

What's new

Updated 2024 AAD guidelines for the management of acne vulgaris.

Background

Overview

Definition
Acne vulgaris is a chronic inflammatory skin condition that predominantly affects late adolescents and young adults.
1
Pathophysiology
The pathophysiology of acne vulgaris is multifaceted, which includes disturbed sebaceous gland activity leading to hyperseborrhea or increased sebum production, dysregulation of the hormone microenvironment, interaction with neuropeptides, follicular hyperkeratinization, induction of inflammation, and dysfunction of the innate and adaptive immunity.
2
Epidemiology
The worldwide prevalence of acne vulgaris is estimated at 1,585 per 100,000 population.
3
Risk factors
Risk factors for acne vulgaris include hormonal influences, particularly androgens that enhance sebum production, most notably in polycystic ovarian syndrome, genetic predisposition with identified susceptibility loci, the use of specific medications, obesity, family history, and environmental factors. The precise etiological triggers of acne, however, remain unclear.
4
5
Disease course
Clinically, acne vulgaris presents with a variety of lesions, including open and closed comedones (blackheads and whiteheads), inflammatory papules, pustules, and nodules and cysts in severe cases. It typically resolves in the late teens or early adulthood, but for some patients, it can persist into later life. Scarring, a potential consequence, can reduce the QoL of patients.
2
Prognosis and risk of recurrence
Acne vulgaris is not a life-threatening condition. However, it can have significant physical and psychological effects.
6

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of acne vulgaris are prepared by our editorial team based on guidelines from the American Academy of Dermatology (AAD 2024), the American Academy of Family Physicians (AAFP 2019), the British Photodermatology Group (BPG/BAD 2019), the Global Alliance to Improve Outcomes in Acne (GAIOA 2018), the French Working Group on Acne (FWG-A ...
Show more

Diagnostic investigations

Microbiological testing
As per AAD 2024 guidelines:
Do not obtain routine microbiological testing in patients with acne.
Consider obtaining lesion culture for the diagnosis of Gram-negative folliculitis in patients presenting with eruptive uniform pustules to nodules in periorificial areas, particularly in the setting of prolonged tetracycline treatment.
Create free account

More topics in this section

  • Endocrinological testing

Medical management

Topical therapies: as per AAD 2024 guidelines, offer multimodal therapy combining multiple mechanisms of action when managing acne with topical medications.
E
Show 5 more

More topics in this section

  • Systemic antibiotics

  • Systemic retinoids

  • Hormonal agents

Nonpharmacologic interventions

Dietary modifications
As per AAD 2024 guidelines:
Insufficient evidence to recommend a low-dairy diet, low-whey diet, omega-3 fatty acids, or chocolate for the treatment of acne.
Recognize that the available evidence on a low-glycemic-load diet for the treatment of acne is conflicting.

More topics in this section

  • Zinc supplements

  • Chemical peels

  • Alternative and complementary therapies

Therapeutic procedures

Intralesional corticosteroid injections: as per AAD 2024 guidelines, offer intralesional corticosteroid injections as an adjuvant therapy in patients with larger acne papules or nodules.
E
use intralesional corticosteroid injections judiciously in patients at risk of acne scarring and/or for rapid improvement of inflammation and pain. Consider using a lower concentration and volume of corticosteroids to minimize the risks of local corticosteroid adverse events.

More topics in this section

  • Laser and light therapy

  • Radiofrequency microneedling

Surgical interventions

Comedo extraction: as per AAD 2024 guidelines, insufficient evidence to recommend acne lesion/comedo extraction for the treatment of acne.
I

Specific circumstances

Pregnant patients: as per N/A 2023 guidelines, recognize the safety profiles of the following therapies for acne in pregnancy:
Situation
Guidance
Contraindicated
Isotretinoin
Spironolactone
Tazarotene
TMP/SMX
Other topical retinoids (such as adapalene, tretinoin, and trifarotene)
Clascoterone
Should be avoided unless for fulminant or refractory acne
Intralesional corticosteroids
Oral corticosteroids
Oral metronidazole
Oral tetracyclines (contraindicated in second and third trimesters)
Light and laser therapies
Can be used for mild-to-moderate acne
Azelaic acid
Benzoyl peroxide
Salicylic or glycolic acids
Topical clindamycin with benzoyl peroxide
Topical sodium sulfacetamide with or without sulfur
Topical metronidazole with benzoyl peroxide
Topical dapsone with benzoyl peroxide
Can be used for moderate-to-severe
Oral amoxicillin
Oral cephalexin
Oral erythromycins (base and ethylsuccinate)
Oral azithromycin
Oral clindamycin

More topics in this section

  • Breastfeeding patients

Patient education

General counseling: as per FWG-A 2017 guidelines, counsel patients with acne regarding the following in order to improve adherence:
treatment (except isotretinoin) is not curative
treatment efficacy is not immediate, regular application and/or intake over several weeks is needed to obtain lesion improvement
maintenance therapy is mandatory once remission has been obtained by the induction regimen
local irritation frequently induced by topical treatments can be prevented by starting with application on alternating days and using moisturizers.
B
Show 2 more